Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: Implications for resource-limited settings

AIDS Reviews

Volumn 8, Issue 1, 2006, Pages 24-36

  Forna, Fatu ^a,b   McConnell, Michelle ^c,d   Kitabire, Florence N ^e   Homsy, Jaco ^e   Brooks, John T ^b   Mermin, Jonathan ^d,e   Weidle, Paul J ^b  

^a Epidemiology Program Office   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

Author keywords

HIV; Hyperbilirubinemia; Kernicterus; Pregnancy; Sulfamethoxazole; Sulfonamide; Trimethoprim

Indexed keywords

ANTIRETROVIRUS AGENT; BILIRUBIN; CARBAMAZEPINE; COTRIMOXAZOLE; DIDANOSINE; DIHYDROFOLATE REDUCTASE INHIBITOR; FOLIC ACID; FOLIC ACID ANTAGONIST; IRON; NEVIRAPINE; PREDNISOLONE; PYRIMETHAMINE; SALAZOSULFAPYRIDINE; SPIRAMYCIN; STAVUDINE; SULFADIAZINE; SULFADIMETHOXINE; SULFADOXINE; SULFAFURAZOLE; SULFAGUANIDINE; SULFAMETHIZOLE; SULFAMETHOXYPYRIDAZINE; SULFANILAMIDE; SULFONAMIDE; TRIAMTERENE; TRIMETHOPRIM; UNINDEXED DRUG; VITAMIN B GROUP; ZALCITABINE; ZIDOVUDINE;

BREAST FEEDING; CARDIOVASCULAR MALFORMATION; CD4+ T LYMPHOCYTE; CHEMOPROPHYLAXIS; CLEFT LIP; CLINICAL TRIAL; DATA ANALYSIS; DRUG EXCRETION; DRUG SAFETY; EMBASE; FEMALE; FIRST TRIMESTER PREGNANCY; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; KERNICTERUS; KIDNEY FAILURE; LIVER FAILURE; MEDICAL LITERATURE; MEDLINE; MORBIDITY; MORTALITY; NEURAL TUBE DEFECT; NEUTROPENIA; PRACTICE GUIDELINE; PREGNANT WOMAN; RASH; REVIEW; SCISEARCH; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TERATOGENICITY; THROMBOCYTOPENIA; URINARY TRACT MALFORMATION; WORLD HEALTH ORGANIZATION;

EID: 33646800135     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Mermin J, Lule J, Ekwaru J, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004;364:1428-34.
2. Chintu C, Bhat G, Walker A, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomized placebo-controlled trial. Lancet 2004;364:1865-71.
3. Zachariah R, Spielmann M, Chinji C, et al. Voluntary counseling, HIV testing and adjunctive co-trimoxazole reduces mortality in tuberculosis patients in Thyolo, Malawi. AIDS 2003;17:1053-61.
4. Badri M, Ehrlich R, Wood R, Maartens G. Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001;15:1143-8.
5. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with TMP-SMZ for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomized trial. Lancet 1999;353:1463-8.
6. Wiktor S, Sassan-Morokro M, Grant A, Maurice C, et al. Efficacy of TMP-SMZ prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomized controlled trial. Lancet 1999;353:1469-75.
7. Kaplan J, Hu D, Holmes K, Jaffe H, Masur H, De Cock K. Preventing opportunistic infections in HIV-infected persons: implications for the developing world. Am J Trop Med Hyg 1996;55:1-11.
8. UNAIDS. Women, Girls, HIV and AIDS - World AIDS Campaign 2004. Available at: http:/www.unaids.org/
9. Ahmad H, Mehta N, Manikal V, et al. Pneumocystis carinii pneumonia in pregnancy. Chest 2001;120:666-71.
10. Koonin L, Ellerbrock T, Atrash H, et al. Pregnancy-associated deaths due to AIDS in the United States. JAMA 1989;261:1306-9.
11. Anonymous. Product information: Septra brand of TMP-SMZ. King Pharmaceuticals, Inc., Bristol, TN, Rev 2/00.
12. Briggs G, Freeman R, Yaffe S. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed. Baltimore: Williams and Wilkins, 1998:986-90,1061-3.
13. Higgins J, Green S, editors. Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8. http://www.cochrane.org/resources/handbook/hbook.htm (accessed November 2005).
14. O'Rourke K, Detsky A. Meta-analysis in medical research: strong encouragement for higher quality in individual research efforts. J Clinical Epid 1989;42:1021-4.
15. UNAIDS/WHO. Provisional WHO/UNAIDS Secretariat recommendations on the use of co-trimoxazole prophylaxis in adults and children living with HIV/ AIDS in Africa. Available at: http://www.unaids.org/
16. International Center for AIDS Care and Treatment Programs at Columbia University. The Columbia Clinical Manual: Care and Treatment of HIV during Pregnancy. Available at: http://www.mtctplus.org/resources.html
17. Ministry of Health, Republic of Uganda. National policy guidelines for co-trimoxazole prophylaxis for people with HIV/AIDS. March 2005.
18. Reid D, Caille G, Kaufmann N. Maternal and transplacental kinetics of trimethoprim and sulfamethoxazole, separately and in combination. CMAJ 1975;112:67S-72S.
19. American Society of Health-System Pharmacists. AHFS Drug information 2003. Bethesda: AHFS, 2003.
20. Maynart M, Lievre L, Sow P, et al. Primary prevention with co-trimoxazole for HIV-1-infected adults: Results of the pilot study in Dakar, Senegal. J Acquir Immune Defic Syndr Hum Retrovirol 2001;26:130-6.
21. Fisk D, Meshnick S, Kazanjian P, et al. Pneumocystis carinii pneumonia in patients in the developing world who have AIDS. Clin Infect Dis 2003;36:70-8.
22. US Public Health Service and the Infectious Diseases Society of America. 2001 USPHS/IDSA guidelines for preventing opportunistic infections in persons infected with HIV. Available at: http://aidsinfo.nih.gov/guidelines/
23. Para M, Finkelstein D, Becker S, et al. Reduced toxicity with gradual initiation of TMP-SMZ as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr Hum Retrovirol 2000;24:337-43.
24. Beutler E. G6PD Deficiency. Blood 1994;84:3613-36.
25. Beutler E. G6PD: Population genetics and clinical manifestations: Blood Reviews 1996;10:45-52.
26. Walker P. Neonatal bilirubin toxicity: A review of kernicterus and the implications of drug-induced bilirubin displacement. Clin Pharmacokin 1987;13:26-50.
27. Morgan A, Wenger N. Sulfadiazine prophylaxis against rheumatic fever during pregnancy: its safety as regards the infant. JMA Georgia 1965;54:153-5.
28. Behrman R, Kliegman R, Jenson H, eds. Nelson Textbook of Pediatrics. 17th ed. Philadelphia: Saunders, 2004:592-9.
29. Ip S, Chung M, Kulig J, et al. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics 2004;114:e130-53.
30. American Academy of Pediatrics, subcommittee on hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics 2004;114:297-316.
31. Porter M, Dennis B. Hyperbilirubinemia in the term newborn. Am Fam Phy 2002;65:599-606.
32. Newman T, Escobar G, Gonzalez V, et al. Frequency of neonatal bilirubin testing and hyperbilirubinemia in a large health maintenance organization. Pediatrics 1999;104:1198-203.
33. Heckel G. Chemotherapy during pregnancy. Danger of fetal injury from sulfanilamide and its derivatives. JAMA 1941;117:1314-6.
34. Ginzler A, Cherner C. Toxic manifestations in the newborn infant following placental transmission of sulfanilamide. With a report of 2 cases simulating erythroblastosis fetalis. Am J Obstet Gynecol 1942;44:46-55.
35. Silverman W, Andersen D, Blanc W, Crozier D. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. Pediatrics 1956;18:614-25.
36. Dunn P. The possible relationship between the maternal administration of sulphamethoxypyridazine and hyperbilirubinaemia in the newborn. J Obstet Gynaecol Br Comm 1964;71:128-31.
37. Brown A, Cevik N. Hemolysis and jaundice in the newborn following maternal treatment with sulfamethoxypyridazine. Pediatrics 1965;36:742-4.
38. Perkins R. Hydrops fetalis and stillbirth in a male glucose-6-phosphate dehydrogenase-deficient fetus possibly due to maternal ingestion of sulfisoxazole. Am J Obstet Gynecol 1971;111:379-81.
39. Speert H. The passage of sulfanilamide through the human placenta. Bull Johns Hopkins Hosp 1938;63:337-9.
40. Barker R. The placental transfer of sulfanilamide. New Engl J Med 1939;219:41.
41. Bomze E, Fuerstner P, Falls F. Use of a sulfanilamide derivative in the treatment of gonorrhea in pregnant and non-pregnant women. Am J Obstet Gynecol 1938:73-9.
42. Lucey J, Driscoll T. Hazard to newborn infants of administration of long-acting sulfonamides to pregnant women. Pediatrics 1959; 24:498-9.
43. Kantor H, Sutherland D, Leonard J, Kamholz J, Fry N, White W. Effect on bilirubin metabolism in the newborn of sulfisoxazole administered to the mother. Obstet Gynecol 1961;17:494-500.
44. Drew J, Kitchen W. The effect of maternally administered drugs on bilirubin concentrations in the newborn infant. J Pediatr 1976; 89:657-61.
45. Morgan A, Wenger N. Sulfadiazine prophylaxis against rheumatic fever during pregnancy: its safety as regards the infant. JMA Georgia 1965;54:153-5.
46. Baskin C, Law S, Wenger N. Sulfadiazine rheumatic fever prophylaxis during pregnancy: does it increase the risk of kernicterus in the newborn? Cardiology 1980;65:222-5.
47. Khan A, Truelove S. Placental and mammary transfer of sulphasalazine. Br Med J 1979;2:1553.
48. Jarnerot G, Andersen S, Esbjorner E, Sandstrom B, Brodersen R. Albumin reserve for binding of bilirubin in maternal and cord serum under treatment with sulphasalazine. Scand J Gastroenterol 1981;16:1049-55.
49. Jarnerot G, Into-Malmberg M, Esbjorner E. Placental transfer of sulphasalazine and sulphapyridine and some of its metabolites. Scand J Gastroenterol 1981;16:693-7.
50. Mogadam M, Dobbins W, Korelitz B, Ahmed S. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981;80:72-6.
51. Levy N, Roisman I, Teodor I. Ulcerative colitis in pregnancy in Israel. Dis Col & Rect 1981;24:351-4.
52. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand 1987;76:137-42.
53. Hohlfeld P, Daffos F, Thulliez P, et al. Fetal toxoplasmosis: outcome of pregnancy and infant follow-up after in utero treatment. J Pediatr 1989;115:765-9.
54. Ratanajamit C, Skriver M, Norgaard M, Jepsen P, Schoenheyder H, Sorensen H. Adverse pregnancy outcome in users of sulfamethizole during pregnancy: a population-based observational study. J Antimicrob Chemoth 2003;52:837-41.
55. Hedriana H, Mitchell J, Brown G, Williams S. Normal fetal outcome in a pregnancy with central nervous system toxoplasmosis and HIV infection. J Reprod Med 1993;38:747-50.
56. Albino J, Shapiro J. Respiratory failure in pregnancy due to Pneumocystis carinii: Report of a successful outcome. Obstet Gynecol 1994;83:823-4.
57. Hicks M, Nolan G, Maxwell S, Mickle C. AIDS and Pneumocystis carinii infection in a pregnant woman. Obstet Gynecol 1990; 76:480-481.
58. Pajor A. Pancytopenia in a patient given pyrimethamine and sulphamethoxidiazine during pregnancy. Arch Gynecol Obstet 1990; 247:215-7.
59. Nelson M, Forfar J. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Brit Med J 1971;1:523-7.
60. Saxen I. Associations between oral clefts and drugs taken during pregnancy. Int J Epid 1975;4:37-44.
61. Hernandez-Diaz S, Werler M, Walker A, Mitchell A. Folic acid antagonists during pregnancy and the risk of birth defects. New Engl J Med 2000;343:1608-14.
62. Hernandez-Diaz S, Werler M, Walker A, Mitchell A. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epid 2001;153:961-8.
63. Czeizel A, Rockenbauer M, Sorensen H, Olsen J. The teratogenic risk of trimethoprim-sulfonamides: A population based case-control study. Reproduct Toxicol 2001;15:637-46.
64. Czeizel A, Puho E, Sorensen H, Olsen J. Possible association between different congenital abnormalities and use of different sulfonamides during pregnancy. Congenital Anomalies 2004; 44:79-86.
65. Jungmann E, Mercey D, DeRuiter A, et al. Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 2001;77:441-3.
66. Pogorzelska E. A case of multiple congenital anomalies in a child of a mother treated with sulfaguanidine. Patologia Polska 1966;17:383-6.
67. Craxi A, Pagliarello F. Possible embryotoxicity of sulfasalazine. Archives of Internal Medicine 1980;140:1674.
68. Newman N, Correy J. Possible teratogenicity of sulphasalazine. Med J Austral 1983;1:528-9.
69. Hoo J, Hadro T. Possible teratogenicity of sulfasalazine. New Engl J Med 1988;318:1128.
70. Richardson M, Osrin D, Donaghy S, Brown N, Hay P, Sharland M. Spinal malformations in the fetuses of HIV-infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reproduct Biol 2000;93:215-7.
71. Rojansky N, Fasouliotis S, Ariel I, Nadjari M. Extreme caudal agenesis: possible drug-related etiology? J Reproduct Med 2002;47:241-5.
72. Williams J, Condie A, Brumfitt W, Reeves D. The treatment of bacteriuria in pregnant women with sulphamethoxazole and trimethoprim. Postgrad Med J 1969;45(Suppl):71-6.
73. Brumfitt W, Pursell R. TMP-SMZ in the treatment of urinary infection. Med J Austral 1973;S1:44-8.
74. Richards I. Congenital malformations and environmental influences in pregnancy. Brit J Prev Soc Med 1969;23:218-25.
75. Ochoa A. Trimethoprim and sulfamethoxazole in pregnancy. JAMA 1971;217:1244.
76. Bailey R, Bishop V, Peddie B. Comparison of single dose with a 5-day course of co-trimoxazole for asymptomatic (covert) bacteriuria of pregnancy. Austr NZ J Obstet Gynaecol 1983;23:139-41.
77. Bailey R. Single-dose antibacterial treatment for bacteriuria in pregnancy. Drugs 1984;27:183-6.
78. Czeizel A. A case-control analysis of the teratogenic effects of co-trimoxazole. Reproduct Toxicol 1990;4:305-13.
79. Torfs C, Katz E, Bateson T, Lam P, Curry C. Maternal medications and environmental exposures as risk factors for gastroschisis. Teratology 1996;54:84-92.
80. Norgard B, Czeizel A, Rockenbauer M, Olsen J, Sorensen H. Population-based case control study of the safety of sulfasalazine use during pregnancy. Aliment Pharmacol and Ther 2001;15:483-6.
81. Schultz L, Steketee R, Macheso A, Kazembe P, Chitsulo L, Wirima J. The efficacy of antimalarial regimens containing sulfadoxine-pyrimethamine and/or chloroquine in preventing peripheral and placental Plasmodium falciparum infection among pregnant women in Malawi. Am J Trop Med Hyg 1994;51:515-22.
82. Parise M, Ayisi J, Nahlen B, et al. Efficacy of sulfadoxine-pyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and HIV infection. Am J Trop Med Hyg 1998;59:813-22.
83. Newman R, Parise M, Slutsker L, Nahlen B, Steketee R. Safety, efficacy and determinants of effectiveness of antimalarial drugs during pregnancy: implications for prevention programs in Plasmodium falciparum-endemic sub-Saharan Africa. Trop Med Int Health 2003;8:488-506.
84. Sowunmi A, Akindele J, Omitowoju G, Omigbodun O, Oduola A, Salako L. Intramuscular sulfadoxine-pyrimethamine in uncomplicated chloroquine-resistant falciparum malaria during pregnancy. Trans Roy Soc Trop Med Hyg 1993;87:472.
85. Shulman C, Dorman E, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anemia secondary to malaria in pregnancy: a randomized placebo controlled trial. Lancet 1999;353:632-6.
86. Burdge D, Money D, Forbes J, et al. Canadian consensus guidelines for the management of pregnancy, labor and delivery and for postpartum care in HIV-positive pregnant women and their offspring (summary of 2002 guidelines). CMAJ 2003;168:1671-4.
87. South African Department of Health. Strategies to reduce mother to child HIV transmission during pregnancy and childbirth. Available at: http://www.doh.gov.za/aids/docs.html.
88. Walter J, Mwiya M, Scott N, et al. Cotrimoxazole prophylaxis and adverse birth outcomes among HIV-infected women in Lusaka, Zambia [abstract 126]. Presented at: 13th CROI, 2006; Denver.